Rob Rigney

Rob Rigney is an experienced business development professional in the pharmaceutical industry with a strong background in dose form development and manufacturing for preclinical, clinical, and commercial needs. Currently serving as Executive Director at AustinPx since June 2022, Rob previously held key positions such as Senior Director & Consigliere at CoreRx, where business and technical support were provided to territorial representatives. This follows a role as Technical VP in Business Development and Marketing at Nucleo Life Sciences before its acquisition by CoreRx. Additionally, Rob has experience as Senior Director of Business Development at Quotient Sciences, Vice President of Business Development and Business Strategy at DSI, and Account Director/Diretor of Business Development at Pharmatek, which was acquired by Catalent. Early career experience includes development and production management at Fluid Air and roles as an Analytical Chemist and Research Scientist. Rob holds a BA in Biochemistry and a BS in Biology, both from Northern Kentucky University, and has extensive expertise in building networks and strategic problem-solving within the industry.